Translating Hepatic Transporter Activity Across Species

Why Cross-Species Translation Needs More Than a Clearance Ratio

A transporter can contribute differently to hepatic drug handling in two species for several reasons: its abundance in the liver may differ, its ortholog may transport the substrate at a different rate, or the substrate may interact differently with other uptake and efflux pathways. A difference in measured clearance therefore cannot automatically be attributed to a difference in transporter abundance. Nor does a larger transporter-mediated uptake capacity, by itself, establish a proportionally larger whole-body clearance.

A useful translation separates how much transporter is present from how active each unit of transporter is. It also asks whether the assay substrate and conditions are relevant to the species comparison. The resulting estimate is a mechanistic scaling calculation, not a substitute for checking whether the model is consistent with in vivo evidence.

This product is useful only when \(q_{T,s}\) and \(A_{T,s}^{liver}\) refer to compatible definitions of active transporter and the same substrate. Abundance should ideally represent functional transporter at the relevant membrane, rather than transcript abundance or total protein that includes intracellular, inactive, or inaccessible transporter. For a measurement reported per gram of liver, total liver amount can be estimated as abundance per gram multiplied by liver mass. If measurements are instead reported per hepatocyte, the corresponding cell number and scaling basis must be used.

Assay Activity and Substrate Specificity

For a transporter-mediated saturable process, a common assay model is Michaelis–Menten uptake:

Here \(v_{T,s}\) is transporter-mediated uptake rate, \(C_u\) is unbound substrate concentration at the transporter, \(V_{\max,T,s}\) is the maximal rate, and \(K_{m,T,s}\) is the concentration at which the rate is half of \(V_{\max,T,s}\). At concentrations well below \(K_m\), dividing rate by unbound concentration gives the low-concentration intrinsic clearance:

Thus \(V_{\max}/K_m\) describes low-concentration activity in the assay system. To obtain \(q_{T,s}\), that activity must also be normalized to the amount of functional transporter in that system. If assay substrate concentrations are not low relative to \(K_m\), compare rates at the same relevant unbound concentration or fit the kinetic model; do not treat \(V_{\max}/K_m\) as the rate at every concentration.

Substrate specificity is comparative, not absolute. A transporter may have a larger \(V_{\max}/K_m\) for one substrate than another, while the rank or magnitude of that preference differs between species. The comparison is meaningful only if the assay systems, concentration definitions, transporter expression, and background corrections are sufficiently comparable.

Constructing a Species-Scaled Estimate

A practical translation starts with a species-specific transporter-mediated clearance estimate and adjusts it for differences in transporter-specific activity and total functional transporter abundance. For an animal species \(a\) and a target species \(h\), the relationship is:

This follows directly by substituting \(CL_{int,T,s}^{liver}=q_{T,s}A_{T,s}^{liver}\) for each species and taking their ratio. It assumes the reported animal value represents the same transporter-mediated process, the activity ratio is measured on a comparable basis, and abundance estimates reflect functional transporter. It also assumes the scaling is appropriate at the substrate concentration of interest; a low-concentration \(q\) ratio may not transfer to a concentration range where transport is substantially saturated.

When abundance is reported per gram of liver, use \(A_{T,s}^{liver}=a_{T,s}W_{liver,s}\), where \(a_{T,s}\) is transporter amount per gram and \(W_{liver,s}\) is liver mass. The activity ratio must not already include the same abundance difference, or abundance will be counted twice. Likewise, an assay rate per total protein is not automatically a rate per transporter molecule.

Assumptions, Diagnostics, and Failure Modes

A cross-species estimate is only as credible as the comparability of its inputs. Before using the scaling equation, check the following:

• Ortholog and substrate relevance. Confirm that the species proteins being assayed are corresponding transporter orthologs and that the substrate is transported by both. Similar transporter names do not guarantee equivalent substrate recognition.
• Comparable activity measurements. Use compatible expression systems and assay conditions, quantify functional transporter where possible, and distinguish transporter-mediated uptake from passive diffusion or other pathways. Inhibitor-sensitive activity is informative only if the inhibitor is sufficiently selective and its effect is characterized in each system.
• Unbound concentration and binding. Compare rates using unbound substrate concentrations at the transporter. Differences in nonspecific binding can create apparent species differences if nominal concentrations are used without correction.
• Concentration range. Check whether the assay concentrations cover the relevant range relative to \(K_m\). A change in \(K_m\) can alter activity at a given concentration even when \(V_{\max}\) is similar.
• Abundance basis. Verify units, membrane localization, and whether abundance is per cell, per gram of liver, or per total liver. Check that the activity normalization and abundance measurement are compatible.

Warning signs include large disagreement among assay systems, activity ratios that reverse across the tested concentration range, unexpectedly high background uptake, or abundance estimates based on transcript levels when functional protein is required. Such findings do not justify selecting whichever value gives the preferred prediction. They indicate that the estimate should be qualified, measured more directly, or reported as a range.

The simple product \(qA\) also omits important features of hepatic disposition. Uptake may compete with passive entry, metabolism, biliary efflux, or return to blood. The amount of substrate available inside the cell can therefore differ from the amount taken up at the membrane. A transporter-mediated uptake capacity should not be equated with net hepatic elimination: intracellular metabolism and efflux can change the disposition of the imported drug. The estimate is also sensitive to disease, induction, inhibition, and population variability if these change transporter abundance or activity.

Alternative Approaches and Their Limits

The activity-and-abundance approach is more mechanistic than scaling a total clearance by body weight or body size, because it targets a defined transporter process. However, it requires transporter-specific activity and abundance data, and errors in either factor multiply in the final estimate. Simple allometric scaling can be a useful empirical comparison when matched transporter data are unavailable, but it cannot identify whether a species difference arises from transporter abundance, transporter function, or other clearance pathways.

Direct human hepatocyte or transporter-system measurements may reduce dependence on cross-species assumptions, but their relevance still depends on assay quality, protein binding, and representation of the in vivo environment. Conversely, a species-scaled transporter estimate can help organize mechanistic evidence, but it should be treated as one component of a hepatic model rather than as an independently validated clinical prediction. Keep the method aligned to the question: transporter-specific capacity, net hepatic disposition, and whole-body clearance are different quantities.

Common Pitfall

A common error is to scale an animal transporter-mediated clearance by the human-to-animal abundance ratio alone, reasoning that more transporter must mean proportionally more transport. That assumes equal activity per transporter across species. If the human ortholog has lower activity per transporter, abundance-only scaling overestimates the human capacity; if its activity is higher, abundance-only scaling underestimates it. The correction is to separate the two factors, use matched activity data normalized per functional transporter where possible, and state when that normalization or the abundance measurement is uncertain.